Please assess the completion status of the following clinical trial:

Trial Title: Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Metastatic melanoma with activating V600 BRAF mutation~* Measurable Tumor~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1~Exclusion Criteria:~* Autoimmune disease~* Active Brain Metastasis (must be stable after radiation for at least one month)~* Prior therapy with immune stimulating agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab + Vemurafenib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).